Chinese biotech company InxMed has recently raised RMB130 million (US$19 million) in a series A+ round financing co-led by China Growth Capital and a fund under Ennovation Venture. InnoMed Capital and Grand Yangtze Capital also participated. Proceeds of the round will be used to accelerate the clinical development and new pipeline layout of product IN10018, […]
China Growth Capital Co-leads Series A+ Round In Biotech Company InxMed comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.